There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 156.
156. In regulation 202 (amendment of regulation 259 (packaging requirements: information for blind and partially sighted patients)), for “for “marketing authorisation” to the end substitute “for “marketing authorisation,” substitute “ UK marketing authorisation, EU marketing authorisation ”.”.U.K.
Commencement Information
I1Sch. 2 para. 156 in force at 31.12.2020 immediately before IP completion day, see reg. 1
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
